



JAN 02 2002 IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Patent  
236.2

#6  
1902  
OIPC

Applicant : Lardy and Marwah  
Application No. : 09/675,323  
Filed : September 28, 2000  
For : THERAPEUTIC TREATMENT OF ANDROGEN RECEPTOR  
DRIVEN CONDITIONS  
Examiner : Peselev, E.  
Group Art Unit : 1623

TECH CENTER 1600/2900

RECEIVED  
JAN 16 2002

RESPONSE TO RESTRICTION/ELECTION REQUIREMENT

Assistant Commissioner for Patents  
Washington, D.C. 20231

Dear Sir:

Pursuant to the Restriction/Election Requirement of September 28, 2001 for the above-referenced application, the following Remarks are respectfully submitted.

REMARKS

*Election Requirement*

The Examiner requires election of a single disclosed species. Applicant elects the compound 1,3,5(10)-estratriene-17 $\alpha$ -ethynyl-3 $\beta$ ,17 $\beta$ -diol, with traverse.

Summary

Applicant asserts that the claimed invention is in condition for allowance and notification to that effect is respectfully requested.

Any fees due in relation to the timely filing of this Response are hereby authorized to be deducted from Deposit Account No. 501536.

Respectfully submitted,

Date: *October 17, 2001*

By:

*Heather L. Callahan*

Heather L. Callahan  
Registration No. 43,524

Hollis-Eden Pharmaceuticals  
9333 Genesee Avenue, Suite 200  
San Diego, CA 92122  
Telephone 858 587-9333 (x204)